statistiche ricercatore

Continente	#
NA - Nord America	791
AS - Asia	543
EU - Europa	277
SA - Sud America	75
AF - Africa	23
Continente sconosciuto - Info sul continente non disponibili	8
Totale	1.717

Nazione	#
US - Stati Uniti d'America	766
SG - Singapore	174
CN - Cina	130
HK - Hong Kong	62
BR - Brasile	58
VN - Vietnam	57
IT - Italia	52
GB - Regno Unito	45
BD - Bangladesh	38
FI - Finlandia	32
SE - Svezia	32
DE - Germania	25
KR - Corea	23
RU - Federazione Russa	22
FR - Francia	20
CA - Canada	11
IN - India	9
NL - Olanda	9
ID - Indonesia	8
JP - Giappone	8
LT - Lituania	8
MX - Messico	8
ZA - Sudafrica	7
BG - Bulgaria	6
PL - Polonia	6
EC - Ecuador	5
EG - Egitto	5
PH - Filippine	5
AE - Emirati Arabi Uniti	4
PE - Perù	4
TR - Turchia	4
CO - Colombia	3
CZ - Repubblica Ceca	3
ES - Italia	3
IQ - Iraq	3
RO - Romania	3
AR - Argentina	2
AT - Austria	2
CR - Costa Rica	2
DZ - Algeria	2
JM - Giamaica	2
KE - Kenya	2
LB - Libano	2
NP - Nepal	2
RS - Serbia	2
TH - Thailandia	2
TN - Tunisia	2
UZ - Uzbekistan	2
AL - Albania	1
AZ - Azerbaigian	1
BH - Bahrain	1
BO - Bolivia	1
CH - Svizzera	1
ET - Etiopia	1
GA - Gabon	1
GE - Georgia	1
GR - Grecia	1
HN - Honduras	1
IE - Irlanda	1
IL - Israele	1
JO - Giordania	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
MA - Marocco	1
ML - Mali	1
MY - Malesia	1
PA - Panama	1
PK - Pakistan	1
PT - Portogallo	1
PY - Paraguay	1
QA - Qatar	1
SC - Seychelles	1
SK - Slovacchia (Repubblica Slovacca)	1
UA - Ucraina	1
VE - Venezuela	1
Totale	1.709

Nome	#
A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon	313
The epidemiology of hepatitis delta infection in Italy	214
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort	202
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B	198
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study	192
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination	186
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications	164
Neutrophil–lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry	132
Molecular diagnostics in hepatitis C virus infection: Clinical applications	116
Totale	1.717

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	70	0	0	0	2	2	7	7	4	10	6	26	6
2022/2023	95	7	13	12	5	13	15	2	12	11	0	1	4
2023/2024	106	3	6	7	10	16	8	15	13	1	2	13	12
2024/2025	399	11	0	10	26	71	59	29	21	53	17	41	61
2025/2026	900	68	50	66	95	146	52	130	42	73	83	46	49
2026/2027	64	20	40	4	0	0	0	0	0	0	0	0	0
Totale													1.717